Overactive bladder/enuresis:

Indications for: MYRBETRIQ

Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, as monotherapy or in combination with solifenacin.

Adult Dosage:

Swallow whole. Initially 25mg once daily; may increase to 50mg once daily as needed or tolerated. Severe renal impairment or moderate hepatic impairment: max 25mg once daily. ESRD or severe hepatic impairment: not recommended.

Children Dosage:

Not established.

MYRBETRIQ Warnings/Precautions:

Severe uncontrolled hypertension: not recommended. Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the tongue, hypopharynx, or larynx occurs. Pregnancy. Nursing mothers.

MYRBETRIQ Classification:

Beta-3 adrenergic agonist.

MYRBETRIQ Interactions:

May potentiate CYP2D6 substrates (eg, metoprolol, desipramine); adjust dose and monitor esp. with narrow therapeutic index drugs (eg, thioridazine, flecainide, propafenone). Concomitant digoxin: use lowest digoxin dose initially (monitor and titrate).

Adverse Reactions:

Hypertension, nasopharyngitis, urinary tract infection, headache; also with solifenacin: dry mouth, constipation, tachycardia; angioedema.


Hepatic (CYP2D6, 3A4).

Drug Elimination:

Renal, fecal.

Generic Drug Availability:


How Supplied:

Tabs—30, 90

Pricing for MYRBETRIQ

50mg tablet (Qty: 30)
Appx. price $435